Brain volume loss is a key marker of degeneration in multiple sclerosis, correlated with future disability progression. Ponesimod, alemtuzumab, teriflunomide, ozanimod, and fingolimod ...
About 10 to 15% of people with the disease have this type of MS. The study looked at rituximab and ocrelizumab, anti-CD20 infusion therapies that target a protein called CD20 found on some white blood ...
The rates were higher in primary progressive MS than in relapsing MS. Patients with multiple sclerosis (MS) have a manageable infection risk profile through long-term treatment with ocrelizumab, ...
A new study, commissioned by the Multiple Sclerosis Society of New Zealand (MSNZ), analysed the cost-effectiveness of Ocrelizumab - which got funded as a treatment for primary progressive multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback